Safety of Continuing Anti-platelet Agents During Colonoscopic Polypectomy: A Prospective Study

Completed

Conditions studied: Post-polypectomy Bleeding, Anti-platelet Therapy, Colonoscopy

In brief

At our VA hospital, in general, it is the policy of our GI lab to not stop our patients anti-platelet therapy whenever they see us for a routine colonoscopy. We do this because we believe the risk of stopping these sort of medications outweigh the risks of a complication from a colonoscopy. Therefore, we are enrolling patients who are either on clopidogrel or prasugrel or not on any anti-platelet/anti-coagulant therapy that come to our GI lab routine colonoscopies. We perform the procedure just like we normally would and then follow-up with the patient 7 and 30 days after their procedure.

Key facts

Study ID

NCT01647568

Run by

Dallas VA Medical Center

People needed

715

Starts

2009-12-01

Last updated by the study team

2012-07-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients presenting to the GI lab for elective colonoscopy

You may not qualify if…

• Patients on Coumadin or other anti-coagulants
• Patients with Inflammatory Bowel Disease

Where it is running

• Dallas VA Medical Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.